GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy: What an Endocrinologist Needs to Know

Hazard ratios for the association between glucagon-like peptide-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy range from 2.19 to 7.74.

• Emerging evidence suggests a possible link between the use of glucagon-like peptide-1 receptor agonists and the risk of developing non-arteritic anterior ischemic optic neuropathy.
• The absolute risk of NAION associated with glucagon-like peptide-1 receptor agonists remains low.
• Patient factors such as optic disc parameters, blood pressure changes, degree of weight loss, and improvement of glycemic control may influence susceptibility to NAION.
• Further research is needed to better understand which specific characteristics may help identify patients at higher risk.

AI simplified